n.a. (SHP)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)

Latest News

Shire To Establish Rare Disease Innovation Hub In Cambridge, Mass.

Shire To Establish Rare Disease Innovation Hub In Cambridge, Mass.

Company to expand into 500 Kendall Street and create a 550,000-square-foot campus focused on rare diseases and highly specialized conditions

Results From Shire's Phase 2 Study Of Maribavir Showed Activity Against CMV Infection In Patients Undergoing Transplant

Results From Shire's Phase 2 Study Of Maribavir Showed Activity Against CMV Infection In Patients Undergoing Transplant

Data support progressing with Phase 3 clinical development program

Invest in Allergan on Weakness, Analysts Say

Invest in Allergan on Weakness, Analysts Say

Pharmaceutical giant Allergan looks poised to have a great year in 2017.

Multimedia Assets Available: Modern Technology And A Multi-Screen Lifestyle Viewed As Important Factors In Rising Prevalence Of Dry Eye Disease

Multimedia Assets Available: Modern Technology And A Multi-Screen Lifestyle Viewed As Important Factors In Rising Prevalence Of Dry Eye Disease

-- Results from the National Eye C.A.R.E. Survey reinforce potential link between tech-dependency and growing risk of dry eye disease

Shire Announces U.S. FDA Approval Of CUVITRU[TM] [Immune Globulin Subcutaneous (Human), 20% Solution] Treatment For Primary Immunodeficiency

Shire Announces U.S. FDA Approval Of CUVITRU[TM] [Immune Globulin Subcutaneous (Human), 20% Solution] Treatment For Primary Immunodeficiency

Approval follows positive data from clinical studies on efficacy and tolerability, as well as infusion time and number of injection sites

Shire's First Prescription Eye Drop, Xiidra™ (lifitegrast ophthalmic solution) 5% Is Now Available in the U.S.

Shire's First Prescription Eye Drop, Xiidra™ (lifitegrast ophthalmic solution) 5% Is Now Available in the U.S.

- Xiidra is the only prescription eye drop approved by the U.S. FDA for the treatment of both signs and symptoms of dry eye disease

VONVENDI, The First And Only Recombinant Treatment For Adults Affected By Von Willebrand Disease, Launches In The U.S.

VONVENDI, The First And Only Recombinant Treatment For Adults Affected By Von Willebrand Disease, Launches In The U.S.

VONVENDI [von Willebrand factor (Recombinant)] is a significant advancement for the treatment of adults with von Willebrand disease (VWD)

Shire Announces FDA Approval Of Adynovate With BAXJECT III Reconstitution System

Shire Announces FDA Approval Of Adynovate With BAXJECT III Reconstitution System

New system reduces number of steps in the treatment process for hemophilia A patients on ADYNOVATE [Antihemophilic Factor, (Recombinant), PEGylated]

ADYNOVATE Phase 3 Efficacy And Safety Data In Children To Be Showcased During International Congress Of The World Federation Of Hemophilia

ADYNOVATE Phase 3 Efficacy And Safety Data In Children To Be Showcased During International Congress Of The World Federation Of Hemophilia

Shire committed to advancing treatment and raising standards of care for hemophilia patients around the world